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Abstract
Health care coverage decisions may employ many different considerations, which are brought together
across two phases. The assessment phase examines the available scientific evidence, such as the cost-effect-
iveness, of the technology. The appraisal then contextualises this evidence to arrive at an (advised) cover-
age decision, but little is known about how this is done.
In the Netherlands, the appraisal is set up to achieve a societal weighing and is the primary place where
need- and solidarity-related (‘necessity’) argumentations are used. To elucidate how the Dutch appraisal
committee ‘constructs necessity’, we analysed observations and recordings of two appraisal committee
meetings at the National Health Care Institute, the corresponding documents (five), and interviews
with committee members and policy makers (13 interviewees in 12 interviews), with attention to specific
necessity argumentations.
The Dutch appraisal committee constructs necessity in four phases: (1) allowing explicit criteria to
steer the process; (2) allowing patient (representative) contributions to challenge the process; (3) bringing
new argumentations in from outside and weaving them together; and (4) formulating recommendations to
societal stakeholders. We argue that in these ways, the appraisal committee achieves societal weighing
rationality, as the committee actively uses argumentations from society and embeds the decision outcome
in society.
Key words: deliberative decision-making; health care decision-making; necessary health care; priority setting; societal
weighing
1. Introduction
Whether a health care technology is made available to patients, for example through a (national)
formulary, benefits package, or insurance scheme, is decided by means of health care coverage
decisions. Making these decisions well is notoriously complex as it leans on a wide variety of
heterogeneous considerations that are brought together in the decision-making process
(Vuorenkoski et al., 2008; Hughes and Doheny, 2011; Cerri et al., 2014; Russell and
Greenhalgh, 2014; Dakin et al., 2015). The most-studied part of this process is the assessment,
which examines the available scientific evidence such as the (cost-) effectiveness of the technol-
ogy, often employing Health Technology Assessment (HTA) methods (e.g. Le Polain et al., 2010;
Franken et al., 2012; Kleijnen et al., 2012; Salas-Vega et al., 2016; Makady et al., 2017). Notably,
such scientific knowledge bases have been shown essential but not sufficient for making good
coverage decisions (Moes et al., 2016; Calnan et al., 2017; Samenleving, 2017; Shirazi et al.,
© The Author(s), 2020. Published by Cambridge University Press on behalf of Health Economics, Policy and Law. This is an Open Access
article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits
unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Health Economics, Policy and Law (2021), 16, 457–472
doi:10.1017/S1744133120000341
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1744133120000341
Downloaded from https://www.cambridge.org/core. IP address: 86.93.153.107, on 28 Sep 2021 at 12:01:55, subject to the Cambridge Core terms of use, available at
2017). Therefore, many coverage decisions feature a second part, sometimes (but not always) a
distinct step in time and space: the appraisal. An appraisal entails the formulation of a (recom-
mended) coverage decision based on contextualisation of the given evidence (Oliver et al., 2004;
Walley, 2007; Patera and Wild, 2014; Jansen et al., 2017; Kleinhout-Vliek et al., 2020). Previously,
contextualisation has broadly been defined as taking into account a variety of values and consid-
erations (Patera and Wild, 2014). Some, such as the English National Institute for Health and
Care Excellence (NICE), has specified contextualisation to mean establishing ‘what is good for
society’, or in other words, providing a societal weighing of the evidence (Culyer and Rawlins,
2004; NICE, 2008; Shah et al., 2013).
How societal weighing works, and how exactly appraisal committees may achieve this,
remains underexplored. Recent descriptive work on deliberative coverage decisions more gener-
ally highlights that these decisions display rationality different from formalised, institutionalised
rationalities generally prescribed for such decisions (Jenkings and Barber, 2004; Russell and
Greenhalgh, 2014; Russell, 2017). We derive three distinct elements of this type of rationality
from the literature. First, this type of rationality utilises different knowledge types. These types
include not only the scientific input deriving from the assessment but often also knowledge pro-
vided by patients as well as ‘local’ knowledge regarding the institutional setting where the
decision-making process takes place. Second, constructing this type of rationality involves
being able to respond appropriately, humanely, to these different types of input and combine
them into one decision, and deal effectively with any tensions that may arise between knowledge
types (Jenkings and Barber, 2004; Gkeredakis et al., 2011; Hughes and Doheny, 2011; Moreira,
2011; Russell and Greenhalgh, 2014; Moes et al., 2016; Calnan et al., 2017). Third, the process
of construction of this type of rationality adheres to substantive requirements, which are generally
in the form of formalised decision criteria as well as processual requirements (Russell, 2017),
often those laid out by the widely-used Accountability for Reasonableness framework (Daniels
and Sabin, 1997, 1998, 2008; Daniels, 2000; Hasman and Holm, 2005). These three elements
would appear, however, to be described for coverage decisions generally, so the question remains:
what does societal weighing rationality look like specifically?
In this study, we will fill the gap concerning societal weighing rationality by examining the
appraisal phase of Dutch health care coverage decisions, which like NICE’s decisions described
above, explicitly aim for a ‘societal weighing’ of the evidence base provided in the assessment
(Zorginstituut Nederland, 2016, 2017). Furthermore, Dutch decision-making practice provides
an excellent case because the appraisal is set up as a separate meeting, a distinct moment in
time and space, making it easier to distinguish from the assessment phase
(Commissie-Dunning, 1991; Stolk et al., 2001, 2002). In the Netherlands, the National Health
Care Institute (in this text: ‘the Institute’, in Dutch: Zorginstituut Nederland), an arm’s length
body, is responsible for advising the Ministry of Health on the contents of the basic benefits bas-
ket. This basket outlines the bare-minimum health care insurance package that is obligatory for
all Dutch citizens. The Dutch coverage decision-making process usually starts with a scoping ses-
sion, in which stakeholders are invited to contribute relevant considerations. This is followed by a
meeting of the Scientific Advisory Committee (‘the assessment committee’, in Dutch:
Wetenschappelijke Adviesraad), in which the scientific knowledge base is established based on
HTA methodology (Franken et al., 2012; Kleijnen et al., 2012; Salas-Vega et al., 2016; Makady
et al., 2017). The Package Advisory Committee (‘the appraisal committee’, in Dutch:
Adviescommissie Pakket), convened once-monthly at the Institute, is subsequently responsible
for the societal weighing of the evidence and the formulation of coverage advice to the
Minister (Couwenbergh et al., 2013; Zorginstituut Nederland, 2016, 2017). The Institute uses
four formalised criteria in this advice, namely effectiveness, cost-effectiveness, feasibility (includ-
ing budget impact considerations), and necessity. ‘Necessity’ is, as a consequence of being a for-
malised criterion, present in the documents providing input for the appraisal as they outline the
available information per criterion. It has, however, also been considered to be established
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especially in appraisal (Mastenbroek et al., 2006; Couwenbergh et al., 2013; Kleinhout-Vliek et al.,
2017; Zorginstituut Nederland, 2017; Kleinhout-Vliek et al., 2020). Therefore, this paper will
explore how the appraisal committee constructs necessity, as this may aid in uncovering elements
that are specific to the achievement of societal weighing rationality (Poley et al., 2002; Stolk et al.,
2002; Hoedemaekers and Oortwijn, 2003).
1.1 Aim
This paper describes the phases of constructing necessity by examining the contents of and the
proceedings at Dutch appraisal meetings through observations, transcriptions, and subsequent
analysis of audio recordings of two meetings. These meetings varied greatly in terms of the type
of health care technology appraised. This is supplemented with interviews with appraisal commit-
tee members and Institute employees (n = 13) and observations of other appraisal meetings (n = 4).
We answer the question: how does the Dutch appraisal committee construct necessity?
2. Methodology
2.1 Approach
In order to explore the Dutch appraisal, we analyse two cases of specific coverage decisions.
Argumentations used to construct necessity that could potentially be employed by the appraisal com-
mittee include, but are not limited to, the morbidity and need experienced by the patient, availability
of alternative treatments, the financial cost per individual patient, and compassion with vulnerable
groups such as children or small numbers of patients generally. These necessity argumentations
are part of a list of 20 argumentation types derived from a realist review of argumentations used
to establish the necessity of coverage of health care technologies worldwide (Kleinhout-Vliek
et al., 2017). For an overview of these 20 inductively-formulated argumentation types, see Table 1.
The Netherlands is a particularly fruitful setting for studying the construction of necessity as the
Dutch use two of these 20 necessity argumentations, namely individual severity of illness (argumen-
tation type ‘Morbidity/Severity’) (Franken et al., 2015; Reckers-Droog et al., 2018, 2019) and the cost
that the individual patient will incur (argumentation type ‘Individual Cost’), as their explicit, a priori
formulated necessity criterion. As such, these two argumentations ought to be present in every deci-
sion document inputting into the appraisal (Stolk et al., 2001; Hoedemaekers and Oortwijn, 2003;
Couwenbergh et al., 2013; Niëns, 2014). Necessity argumentations are of interest for two reasons.
First, these argumentations are employed not only by professional decision-makers but also by
other parties, such as patients and other societal stakeholders, who may also be present at the
appraisal meeting (further information below). Second, necessity argumentations are variable in
usage as their perceived validity and allotted weight differs per decision, making their patterns espe-
cially vivacious (Kleinhout-Vliek et al., 2017; Kleinhout-Vliek et al., 2020).
To study necessity argumentations in appraisal we have chosen a case approach (Ragin, 2004;
Creswell and Poth, 2017) because researching a similar process in a variety of situations is con-
sidered helpful for gaining insight into commonalities across situations, especially when it con-
cerns context-dependent social processes (Lamont, 2012; Dussauge et al., 2015). In this, we hold
that the context is case-specific and thus differs per decision situation (Asdal, 2012; Asdal and
Moser, 2012). The cases chosen concern two health care technologies, namely eculizumab
(Soliris®) and front teeth replacement therapy. These cases are relatively run-of-the-mill; only ecu-
lizumab was sparingly discussed in the Dutch media (Berkhout, 2017). They share two character-
istics that resulted in their selection. First, the cases vary widely in terms of the type of technology,
price, and a number of patients affected, but with necessity argumentations playing a pivotal role
in both, as suggested in informal conversations by contacts at the Institute (front teeth replace-
ment therapy) or the literature review [eculizumab (Soliris®)] (Kleinhout-Vliek et al., 2017).
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Second, the appraisal meetings took place in 2015 and 2016, meaning that the first author could
be present at the appraisal meeting (see Table 2).
2.2 Methods
Our dataset comprises two cases. The data on these cases were gathered through observations,
transcription of audio files, documents, and interviews. The Institute consented to the first author
accessing the setting of the appraisal committee through an explicit invitation by the secretary of
Table 1. Overview of the 20 argumentation types that fall under the necessity criterion and their respective descriptions
(Kleinhout-Vliek et al., 2017)
Argumentation type Description
Definition of Illness Whether the ailment is considered an illness for which treatment is necessary
Dignity Whether (lack of) coverage is considered to affect the dignity of the patient to such an
extent that it needs to be amended
Equity/Fairness/Justice Whether coverage would be necessary to counter injustice/inequity/lack of fairness in
(access to) treatment
Human Right Whether (lack of) coverage is considered to affect the human rights of the patient to
such an extent that it needs to be amended
Individual Cost Whether lack of coverage would stop patients from buying necessary care themselves
due to prohibitive cost
Individual
Responsibility
Whether the individual is considered responsible for paying for this treatment
Medical Necessity Whether or not a treatment is considered to be ‘medically necessary’ or a ‘medical
necessity’
Morbidity/Severity Whether the physical and/or psychosocial morbidity associated with a certain ailment
constitutes such a need that coverage is considered necessary
Moral Hazard Whether there is considered to be a possibility of over-usage (i.e., unnecessary increase
in demand, when people use more than they need as a result of coverage)
Need The extent to which the patient is considered to be in need for which treatment is
necessary
(No) Alternative Whether or not viable alternatives are considered to be present which would make
coverage more or less necessary
Patient-Diagnosis Whether an illness is self-reported rather than diagnosed by a doctor
Range of Normality Whether the experience of the patient is considered normal or abnormal to such an
extent that coverage is deemed necessary
Rule of Rescue Whether the identifiability of individuals close to death is considered to heighten the
necessity of coverage




Whether the small size of the patient population is considered to heighten the necessity
of coverage (due to, amongst others, the inequality in terms of research expenditure
or difficulties in obtaining high-quality data)
Societal Impact Whether coverage is considered necessary to allay the impact this disease has on people
beyond the patient
Societal Functioning Whether coverage would aid a person’s necessary functioning in society
Societal Responsibility Whether society is considered responsible for paying for this treatment
Vulnerability/
Compassion
Whether a compassionate response to vulnerable groups, e.g. children, in the form of
coverage is considered to be a necessity
460 Tineke Kleinhout‐Vliek et al.
https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1744133120000341
Downloaded from https://www.cambridge.org/core. IP address: 86.93.153.107, on 28 Sep 2021 at 12:01:55, subject to the Cambridge Core terms of use, available at
the committee. This invitation included the ‘closed’ pre-meeting for the eculizumab case. The
secretary also provided audio-recordings s/he used to write minutes to be analysed for this
study. The first author was present at both appraisal committee meetings, where she observed
and took field notes. These notes were supplemented by audio files of the same appraisal com-
mittee meetings, which were transcribed verbatim. Moreover, we analysed five documents per-
taining to these cases. For both cases, this entailed the document that was provided to the
appraisal committee (the ‘discussion document’) and the final ‘appraisal report’ supplemented
by the patient contribution for eculizumab (see Table 2). For the documents, only the main
body of text was analysed (i.e., excluding appendices).
For triangulation purposes, the first author interviewed seven policy advisers (‘Institute
employees’), some of whom worked on the cases. She also interviewed six appraisal committee
members present at the meetings, some of whom were interviewed multiple times, to a total
of 13 people over 12 interviews (for a precise overview of who was interviewed when, please
see Table 2). All approached interviewees consented to be interviewed, except one Institute
employee, who declined due to a full schedule. Three interviews were group interviews (type:
field-formal, meaning that the questions were of a semi-structured nature and that the interviewer
took on a somewhat directive role) (Frey and Fontana, 1991). Institute employees 2 & 5 and 1 & 7
were interviewed in pairs at the request of the employees themselves, as they considered their
answers would supplement one another (in the former case, the interviewer did not know two
people would be present until the moment of the interview). The group interview with committee
members 1, 4, 5 & 6 was done out of convenience, as committee members are often only present
at the Institute once a month, so this presented a good opportunity. Again, the interviewees con-
sidered their answers to complement one another. Oral informed consent was given for use of
interview data, written informed consent was given for publication, and a formal waiver for eth-
ical approval was obtained from the Medical Ethics Committee (in Dutch: Medisch Ethische
Toetsings Commissie) at the Erasmus Medical Centre, Rotterdam, the Netherlands (reference
number: MEC-2017-539. The interviews were conducted by the first author using a topic list
with non-structured, open-ended questions, and the interviews were audio-recorded and subse-
quently transcribed verbatim. The topic list included for Institute employees: how this technology
arrived at the Institute agenda, the scoping session, how they retrieved any additional informa-
tion, the appraisal meeting, how they arrived at the text in the different documents, and more
general topics pertaining to the Institute. This was done to gain deeper insight into the working
processes at the Institute, especially concerning different forms of input for the appraisal meeting.
For committee members, the topic list concerned the appraisal committee’s functioning generally,
how different types of information are usually dealt with, and specific experiences they could
recall. These questions were formulated to gain insight into the cases, but also to obtain reflec-
tions on tentatively formulated phases of necessity construction. Lastly, all interviewees were
probed about necessity argumentations.
Table 2. Overview of data collected pertaining to the case studies
Case
Observations and
audio files Documents Interviews







2.1 discussion document Institute employee 3
(April 2015)
2.2 appraisal report Institute employee 4
(May 2015)
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This dataset was analysed as follows. The list of 20 necessity argumentations (Kleinhout-Vliek
et al., 2017) was used as sensitising concepts to guide the first step of the detailed content analysis
of the documents and transcribed committee meetings, in which the necessity argumentations were
used as a list of codes (Table 1). The explicit mentioning, ‘black on white’ or ‘out loud’, of necessity
argumentations was tracked across the documents and audio files through coding specific utterances
as one or more of the argumentation types, using Microsoft Excel to put utterances that had received
the same code together in the same row. The first tentative patterns were subsequently elucidated
based on this tracked argumentation use. For the formulation of the phases, we chose a chronological
and person-dependent (first this person spoke, then that person contributed) rather than substantive
(these argumentations were used more often than those) patterning. These patterns formed the basis
for the different phases, formulated and refined in further extensive discussions within the author-
ship team, then supplied and solidified by information retrieved from the interviews. These inter-
views specifically clarified the dynamics around the Institute employees’ and the patient and
patient representatives’ contributions. Additional observations served to see whether data saturation
was achieved (Table 3). A member check with the appraisal committee and several personal com-
munications (committee meetings of October and December 2016 and February 2017, the audio file
of a committee meeting of January 2015, member check through a presentation to the committee on
14 April 2018, personal communications with committee members 5, 6, and 7) to see whether the
interpretation made by the authors stayed close enough to the interpretation of those observed
(Sayer, 2011) (see also Table 3). Especially the member check and the personal communications
have positively impacted the reliability of the study in this regard; the personal communications fol-
lowed the member check to clarify the interpretation of our data in a number of places, these are
indicated in the text through reference to ‘(interviewee X, personal communications)’.
3. Results
This section first describes the working procedure of the Institute and the appraisal committee, suc-
ceeded by an introduction to the case studies and a description of the general setting, and finally
descriptionsof theway inwhichnecessity is constructedperphase of the appraisal committeemeeting.
3.1 Working procedure
The Institute’s working procedure for formulating an advised decision follows the general
assessment-appraisal pattern (Patera and Wild, 2014). Agenda setting varies and may happen
Table 3. Overview of additional data collected
Committee meetings
Observations and audio files Interviews
January 2015 Audio file only Committee member 5 (March 2015)
October 2016 Institute employee 6 (March 2015)
December 2016 Observations only Committee member 3 (August 2015)
February 2017 Observations only Committee member 2 (September 2015)
Committee member 5 (October 2016)
Institute employees 2 & 5 (October 2016)
Institute employees 1 & 7 (October 2016)
Committee member 1 (February 2017)
Committee members 1, 4, 5 & 6 (February 2017)
Committee member 6 (October 2017)
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through pharmaceuticals gaining market access or by another party, such as the Minister of
Health or a professional organisation. Once it is placed on the agenda, one or two Institute
employees take responsibility for this dossier; in this study, these were different people for
each case. After a scoping session with interested parties, the scientific evidence reports are writ-
ten by other Institute employees with expertise in therapeutic value, cost-effectiveness, and bud-
get impact. These are bundled and combined with a short explainer by the one or two Institute
employees who hold final responsibility for this dossier to benefit the assessment phase. The
assessment phase takes place at Scientific Advisory Committee, the assessment committee in
this text (in Dutch: Wetenschappelijke Adviesraad, WAR), based on which an assessment report
is composed by the secretary of this committee. This report provides a summative conclusion on
the valuation, the size, and the probability of the effect of the medicine. This assessment report is
sent to the stakeholders for a consultation and consequently combined with input from the scop-
ing session as well as a fresh explainer into a ‘discussion document’ by those responsible for this
dossier. This is aided by the secretary of the assessment committee and approved by the secretary
and chair of the appraisal committee, to benefit the appraisal phase (committee member 5, per-
sonal communications) (Zorginstituut Nederland, 2017).
The appraisal subsequently takes place at the meeting of the Package Advisory Committee (in
this text: the appraisal committee). The committee is comparatively small (Patera and Wild,
2014): it comprises eight to ten external experts (e.g. in medical ethics, pharmaco-economics,
or medicine), who are not employed by the Institute. Like NICE’s Social Value Judgements,
the Dutch appraisal explicitly aims for a societal weighing of the provided scientific evidence
(Couwenbergh et al., 2013; Zorginstituut Nederland, 2016, 2017).
The appraisal committee members read the assessment report in advance of the meetings. All
meetings, which are in principle open to the public, are preceded by a ‘closed’ meeting, in which
patients and their representatives were absent but the Institute employee(s) responsible for the
dossier were present, and the files are already discussed (observations February, November
2015, October, December 2016, and February 2017, see also Zorginstituut Nederland, 2016).
3.2 Cases
We studied the appraisal deliberations for two significantly varying cases, eculizumab and front
teeth replacement therapy.
Eculizumab (Soliris®) is an orphan drug currently licensed for Atypical Hemolytic Uremic
Syndrome (aHUS) and Paroxysmal Nocturnal Hemoglobinuria (PNH). After four years of pro-
visional coverage, which is a temporary coverage arrangement, the final advised decision to the
Minister was to be drafted by the Institute in 2016. The discussion document (document 1.1)
states that there is a debate on whether the incremental cost-effectiveness ratio (ICER) for treat-
ment of aHUS with eculizumab approximates the reference value at €80,000 per QALY for severe
diseases. The calculated cost-effectiveness ratio was thus considered highly unfavourable, but clin-
icians and patient organisations had initiated independent research on shortening the treatment
period through improved start-stop criteria, which was expected to result in a more favourable
ICER. A grant was already obtained for this research (though not for actual medicine). After
the formal presentation by the Institute employee responsible for the file came the contributions
of one patient and two patient representatives (in this case, the mother of a patient and a clin-
ician). Especially the mother’s emotional contribution was followed by an extended silence on
the part of the committee, and many committee members vocalised their appreciation of these
contributions. For the deliberations, the research on the new protocol was the primary focal
point. The committee thought investing in this a worthy cause; the final advised decision stressed
that the committee considered the initiative so commendable that it needed to remain possible to
reimburse eculizumab from public funds within the research protocol (document 1.2). Relief on
the part of the patients was palpable; the chair suggested the committee take a break, and the
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patient (representative)s were congratulating each other, also a few committee members offered
their congratulations (observations/audio file 1).
Front teeth replacement was discussed in the appraisal committee in February 2015 after the
College of Dentists (in Dutch: College van Adviserend Tandartsen) placed it on the agenda
through contact with Institute employees 3 and 4. The reason provided was that current legisla-
tion was perceived as a perverse stimulus, the situation being as follows. All dental care is covered
by the Dutch basic benefit package until the insured’s 18th birthday, but not afterwards. This
means that when young people lose their front teeth or were born without them, they may prefer
to have them replaced before their 18th birthday (as the costs are approximately €3500 for front
teeth implants), whereas it is often better to do so later as the oral cavity is not fully grown until
the age of 22. In the appraisal committee meeting where the coverage of front teeth implants was
discussed, the topic was not considered of major importance or interest, even a little laughable,
for its small budget impact (observations/audio file 2, interview with Institute employee 5).
Institute employees 3 and 4 were especially aware of its political history; one regarded it as a mis-
take that could have been prevented that current legislation did not specify the extended coverage
until the age of 22. The discussions in the appraisal committee seemed relatively straightforward,
with everybody leaning in the direction of extending coverage until one committee member
apparently wanted to stimulate the discussion by deliberately going against the tide (paraphrase,
interview Institute employee 3). This resulted in a longer discussion, with the final decision
apparently taken for pragmatic reasons (namely the time it would take to change the legislation;
coming back to it in the appraisal meeting next month would mean another year’s extension)
(observations/audio file 2). The final advised decision, then, was that as long as the claim was
made before the 18th birthday, coverage would be continued until the age of 22 (document 2.2).
3.3 General setting
The meetings of the appraisal committee take place in a sizeable meeting room that is rela-
tively light, even though the blinds are drawn. There are two entrances: you can enter the
room from ‘within’ the building (behind the security gates) but also from the ‘outside’, pro-
vided your name is on the list, which is checked at the reception. Ten people are seated
around tables set up in a large square. There are thermoses with coffee and tea and plates
of biscuits. An ‘audience’ of eight more people, including me, sits on the rows of chairs
set up on one side of the room, where we can see the committee and the presentation screen
well. I seem unable to shake the feeling we are watching a staged performance. It is clearly
one of these occasions where you feel conscious of making noise: I open my water bottle as
quietly as possible. Given this fairly formal setting, I am struck every time by how warmly the
committee members greet one another when they come in, how at-home they seem (one even
brought her dog!), and even more by the apparent light-heartedness of it all, the sheer good
humour that characterises the proceedings. (Condensed field notes, observations 1 and 2)
In this setting, the deliberations on the two cases followed approximately the same order. We
have separated this order out into four phases, namely (1) the contribution of the Institute
employee(s); (2) the contributions of the patient(s) and/or their representative(s); (3) the actual
deliberations of the committee; and (4) the formulation of the decision. This separation into four
phases allows us to show how necessity is constructed in each phase.
3.4 Phase 1: institute employee(s)
The contribution of the Institute employee(s) is the first of four phases we distinguish in the
Dutch appraisal meeting, and we will show the impact of these contributions on the committee
deliberations that followed.
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In our observations, after the meeting was formally opened by the chair the Institute employee
was invited to summarise the assessment report by means of a presentation. This presentation
contained information on the individual severity of illness (code: Morbidity/Severity, the codes
correspond to argumentation types in Table 1) and costs per the individual patient (code:
Individual Cost). These two are formulated as official, explicit elements of the formalised neces-
sity criterion (Couwenbergh et al., 2013). Notably, the appraisal committee subsequently took the
individual severity of illness and costs per individual patient as ‘given’ in their deliberation that
followed; we noted they did not explicitly mention them (observations/audio files 1 and 2). As a
committee member explained afterwards, the reason for this lack of use of the severity of illness
and costs for the individual by the committee is that it is not their mandate to weigh these expli-
citly (committee member 4, personal communications). This does not mean the Institute
employee’s input is considered ineffective. In an interview, one committee member commented
on the introduction by Institute employee(s) that:
CM5 [T]he discussion, at some point, heads into a different direction.
CM6 Yes, that’s right. (Group interview with committee members 1, 4, 5 and 6)
They acknowledged the impact on the deliberation: the Institute employee’s argumentations
deriving from formalised criteria are considered authoritative and steering the direction the
committee’s discussion takes.
In sum, necessity is constructed by the appraisal committee not by weighing the formalised
necessity criteria contributed by the Institute employee explicitly, but instead by allowing them
to steer the appraisal process implicitly, which committee members consider to positively impact
the deliberations.
3.5 Phase 2: patient (representative)(s)
For the second phase of the appraisal, which consists of the contribution(s) of the patient
(representative)(s), we will also describe how they affect the deliberations of the committee.
During the appraisal meeting for the eculizumab case, we observed how patients and/or
patient representatives, in this case, a mother and a medical doctor, gave a short statement fol-
lowing the Institute employee (observations/audio file 1). Interestingly, the necessity argumenta-
tions that patient (representative)s contributed were not mentioned by the appraisal committee.
For example, the patient representative mentioned that the decision-making process was:
[A] story (…) that concerns (…) justice. (Document 1.3 and observations/audio file 1, code:
Equity/Fairness/Justice)
Not only is [coverage] the best option for the doctors and us; it is also for society as a
whole. (Document 1.3 and observations/audio file 1, code: Societal Impact)
We observed that neither of these argumentation types was mentioned by the appraisal commit-
tee (observations/audio file 1). The patient representative also brought in two argumentation
types that were repeated once but not discussed further. First:
As of [29 October 2014], the life of our little daughter Rosa, just 1 year old, forever lost its
ease and was never again taken for granted. (Document 1.3 and observations/audio file 1,
code: Vulnerability/Compassion)
This clear call for compassion with eculizumab patients, and Rosa, in particular, was repeated
by committee member 7 (observations/audio file 1), but not discussed by the committee.
Thus, the committee did not explicitly weigh the patient (representative)(s)’ contributions.
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Notably, however, patient (representative)(s)’ contributions were a primary topic of discussion
during the interviews with committee members. Several committee members commented on
what they experience when ‘faced with’ patients and their representatives during the appraisal:
We need to keep the distance [from the patients]. [With emphasis:] Someone needs to keep
the distance. And it should be us. (…) It’s like a war, the generals have to decide where the
bombs will fall, and they should not see the mess it creates. (Committee member 2, inter-
view)
[A good decision] requires a kind of distance from that specific [patient perspective].
(Committee member 3, interview)
To function well, the committee members feel they require metaphorical distance from the
patients, which helps explain the lack of explicit discussion of argumentations contributed by
patients or their representatives. Another committee member reflected in personal communica-
tion on the topic:
The patients challenge the committee to keep their position. (…) You need to stay detached.
[But the patients’ input] gives handles for substantiating [your position]: you must explain it
well. It challenges you as a group and as a person. (Committee member 7, personal
communication)
This committee member suggested that the patients’ input increases the quality of the final
(advised) decision and its substantiation as the process is ‘challenged’ by the contributions.
Summarising, necessity is constructed by the committee during the deliberations by not
weighing the patient (representative) contributions explicitly, but by allowing them to challenge
the decision-making process implicitly, which committee members consider heightens the quality
of the justification or rationale for the decision.
3.6 Phase 3: deliberation
The next phase we describe is the deliberative discussion by the committee, where many different
argumentations are contributed by the committee.
In our observations, the deliberative discussion was initiated by the chair, with ample oppor-
tunity for the other committee members to speak and to respond to one another. The professed
goal of the discussion is to ascertain whether there may be reasons to deviate from the reference
value for cost-effectiveness (committee member 5, personal communications), which range in
three classes from 10 to 80,000 euro per Quality-adjusted Life Year (QALY). If the cost-
effectiveness falls within a certain reference value range given a certain individual severity of ill-
ness, it is classed as favourable; if it does not, it is classed as unfavourable (Zorginstituut
Nederland, 2017, 2018). We observed how the discussions both started and ended with a
‘round’ around the meeting table, where committee members were invited to speak in turn. In
the deliberative phase of the meeting, members make statements and respond to one another
before the final decision (observations/audio files 1 and 2). The deliberations were subsequently
summarised by the chair of the committee.
In interviews, both committee members and Institute employees describe the appraisal as an
‘open, moral’ place ‘with permeable borders’ where many ‘things’ interact ‘organically’ to form an
advised decision (committee members 2, 6, 4, Institute employee 4, (group) interviews).
Specifically, the observational data show that necessity is constructed during the deliberations
by bringing new argumentations together. In the front teeth case, one appraisal committee mem-
ber asked whether front teeth replacement therapy was potentially a form of cosmetic surgery,
which would decrease the necessity of coverage significantly (as the absence of front teeth
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would be seen as relatively normal and the therapy thus as a cosmetic intervention; code: Range
of Normality). In response, other committee members highlighted the importance of making sure
young people are able to do normal things like eating an apple (audio file 2, code: Societal
Functioning). This tension was resolved by one committee member, who humorously brought
the following new necessity argumentations together:
I had a strange association with the contraception debate, where we said, "You should pay for
that yourself”, but up to a certain age, we think that it needs to be reimbursed because of the
situation that, just, for example, a 14, 15-year-old with parents who think otherwise would
not be able to – that it could result in unwanted pregnancies, and we would like 18-year-old
girls to enter adulthood without an unwanted pregnancy. [Laughter] They must both have
good teeth and not have an unwanted pregnancy! [Laughter] (Committee member 9, obser-
vations/audio file 2, codes: Similar Treatments and Vulnerability/Compassion)
From this quote, we see how this committee member brought in new argumentations through
comparison with contraceptives, which is covered in the basic benefits package for under-18s
(and thus heightening the necessity of coverage; code: Similar Treatments). S/he also brings it
together with argumentation of compassion with a 14, 15-year old whose parents might not
be able to afford this therapy (code: Vulnerability/Compassion). This was confirmed in an inter-
view, where a committee member described the general process as follows: the appraisal commit-
tee ‘brings in’ new necessity argumentations ‘from the outside’ to be ‘woven together’ (committee
member 1, interview). In fact, this bringing in from the outside is part of their official task (art.
14, Zorginstituut Nederland, 2016). Sources of such new argumentations from the outside also
include newspapers (as observed during committee deliberations, audio file committee meeting
January 2015).
In sum, necessity is constructed in this phase by bringing in new argumentations derived from
the outside, from society, with sources including newspapers and previously-taken decisions, and
weaving these considerations together.
3.7 Phase 4: decision
In the final phase of the appraisal, the committee formulates its positive or negative coverage
decision advice.
In this phase, we observed how the committee not only formulated the decision but also gave
additional recommendations, generally phrasing their coverage advice as: ‘yes, provided that…’ or
‘no, unless…’ (observations/audio files 1 and 2). From our observations, it became clear that the
research on the protocols outlining new start-stop criteria was crucial in the deliberations on ecu-
lizumab’s coverage status and the final decision. The committee spent a lot of time outlining the
tension between the high price and corresponding cost-effectiveness ratio and the risks the
patients were willing to take by stopping treatment with eculizumab for a shorter or longer period
under these new, to be researched further, protocols (observations/audio file 1). In the end, the
advised decision to the Minister of Health was positive, with the strong recommendation that the
research on the protocols containing the start-stop criteria would continue (document 1.2).
Furthermore, we observed that the positive decision including recommendations was supplemen-
ted by committee member 13. S/he recommended that the eculizumab expertise centre respon-
sible for the research would communicate the desire to pressurise the manufacturer for better
pricing of eculizumab to other countries (observations/audio file 1).
The committee thus gives recommendations to a broad set of societal stakeholders including
the manufacturer, the professional organisations involved in research, in addition to the Minister
of Health. We analyse this dynamic as a way of completing the construction of necessity: with
these recommendations, the decision is embedded in society as it is linked directly not just to
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patients and the Minister of Health, but to other societal stakeholders who will impact what care
entails in practice.
4. Discussion
To describe how necessity is constructed in Dutch health care coverage decisions, we followed the
use of necessity argumentations across meetings of the appraisal committee at the Dutch Health
Care Institute, supplemented by document analysis and interviews. Necessity is constructed by
the appraisal committee by first, allowing explicit criteria contributed by the Institute employee
to steer the process; and second, by allowing patient (representative) contributions to challenge
the process. The third element of necessity construction we identify is bringing in new argumen-
tations from the outside, from society, and weaving them together carefully. Fourth and finally,
necessity is constructed by the appraisal committee through formulating recommendations to
societal stakeholders, thus making the decision more societally embedded than a tersely formu-
lated ‘yes’ or ‘no’.
In the introduction, we outlined our interest in societal weighing rationality and concluded
that achieving rationality in health care coverage decisions generally comprises (1) understanding
different types of knowledge and (2) combining them into one decision, whilst (3) adhering not
only to substantive requirements, but also processual ones (Jenkings and Barber, 2004;
Gkeredakis et al., 2011; Hughes and Doheny, 2011; Russell and Greenhalgh, 2014; Calnan
et al., 2017; Russell, 2017). In terms of societal weighing rationality specifically, we conclude
that all three elements are confirmed by our dataset on constructing necessity to a certain extent.
The committee meeting indeed features different types of knowledge. In this dataset, these con-
tain on the one hand argumentations representing scientific knowledge contributed by the
Institute employee (individual cost and severity of illness), and on the other hand, also the patient
(representative)’s experiential knowledge. We show that although these considerations are gener-
ally not mentioned explicitly by the committee, they are considered to steer the discussions impli-
citly and to heighten the quality of the deliberations and the justification or rationale, respectively.
Our dataset shows that during the deliberations, the committee does combine many argumenta-
tions, thereby also confirming the second element of rationality, and would appear to do so
according to substantive and processual requirements laid down in policy documentation as
per the third identified element (Couwenbergh et al., 2013; Zorginstituut Nederland, 2017),
though the latter was not an explicit topic of study. This overlap with previously-described cover-
age decision rationality, we argue, indicates that these parts of constructing necessity may indeed
be classified as elements of not only health care coverage rationality, but societal weighing ration-
ality. This overlap between necessity construction and societal weighing rationality is even more
evident for the latter two phases of constructing necessity, as they show how argumentations are
brought in from society (in our dataset, sources included previous decisions but also newspapers),
and how the (advised) decision is embedded in society (through recommendations to societal sta-
keholders) in turn. These two elements give a distinct flavour to societal weighing rationality that
other studies of health care coverage decision making appear not to have hit upon to date.
The reluctance in terms of explicitly weighing the experiences of individual patients has pre-
viously been described for a variety of settings (Carlsen and Norheim, 2005; Rooshenas et al.,
2015; Hashem et al., 2018). One potential underlying reason may be what Moreira describes
as ‘the politics of singularities’. Personal stories, according to Moreira, have a strong allegorical
character by which they may spark the imagination through being relatable, and are thus able
to destabilise other argumentations (Moreira, 2012). This fact that the committee listens to but
does not explicitly mention these argumentations may be a manifestation of a refusal to be
drawn into such politics. Regardless of the underlying reason, this finding is fascinating in
light of widespread attempts to draw patients and citizens into such decision-making processes
(Wait and Nolte, 2006; Mitton et al., 2009), also termed a ‘multi-stakeholder appraisal’
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(Abrishami et al., 2017). Our data underline that this will not be easily achieved, which is in line
with earlier work on the practices of dealing with different types of knowledge in health care
coverage settings (Moes et al., 2016; Hashem et al., 2018).
On the recommendations specifically, the brunt of the available literature covers the process of
coming to these decisions and the rationales behind them, rather than looking at what the add-
itional recommendations might be (cf., Giacomini et al., 2000; Singer et al., 2000; Martin et al.,
2001; Madden et al., 2005; Bukachi et al., 2014; Byskov et al., 2014; Rooshenas et al., 2015).
Follow-up research may address questions on whether other appraisal committees also give
recommendations, on the underlying dynamic these recommendations may point to, the role
these recommendations play, and their implications for the process of health care coverage deci-
sions generally.
4.1 Strengths and limitations
This paper describes how a coverage appraisal is performed by decision-makers and the dynamics
of using argumentations therein. To our knowledge, this study adds to existing research on cover-
age decisions both methodologically, through showcasing how insight can be generated by tracing
argumentation types across documents and deliberative settings, as well as content-wise, noting
what societal weighing rationality entails specifically. It contributes to the literature of elegant
muddling through by showing the emergent shared systematics behind it (Calnan et al., 2017;
Russell, 2017). Moreover, it shows how pragmatic rationality is accomplished collectively; it is
not just the committee, but also the Institute employees and the patients that crucially shape
the deliberations.
The methodology chosen will have impacted the data; the dataset comprises a mixture of nine
individual and three group interviews. Though both interview types were held primarily for pur-
poses of data triangulation, the data gathered in these settings will have differed. In group inter-
views, the members of the group may stimulate each other (rather than the researcher being the
only one to take this role) in terms of encouraging recall, opinion elaboration, and variation in
response. However, group members may also correct each other and even sway each other’s opi-
nions. Influential herein are group size, familiarity, and power dynamics (Frey and Fontana, 1991;
King et al., 2018). In this dataset, two of the three group interviews were with two direct Institute
employee colleagues, who seemed high on familiarity and relatively low on power dynamics, posi-
tively impacting the data gathered. Interviewees did indeed often supplement each other; both
double interviews were, in fact, suggested by the interviewees themselves for that reason. The
third group interview, with four appraisal committee members, also concerned peers who were
comfortable expressing their opinions together. Moreover, in this case, the ‘quieter’ respondents
were interviewed separately as well.
A major limitation of this study is the focus on two cases. It is relatively common to only focus
on one case for characterising these types of decision making (Moreira, 2011; Moes et al., 2016).
The case approach has granted us increased reliability but may necessarily lack some in-depth
acquaintance with each case. Another limitation is the focus on the deliberations in the appraisal
committee meeting only. Other studies focus on the ‘back stage’, thereby uncovering more work
that is done ‘behind the scenes’ to accomplish these types of deliberations (e.g., Escobar, 2015).
Future research could attempt to visualise both, especially elucidating how the two intermingle in
practice (cf. Hajer, 2005).
5. Conclusion
Using heterogeneous argumentations to make well-justified decisions is a task that many public
institutions work hard to complete astutely. This paper gives insight into the processes of tackling
this task in a particularly vibrant field: health care coverage. It does so through examining the
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construction of necessity in the deliberative appraisal of two Dutch coverage decisions by follow-
ing the necessity argumentations as mentioned by the different parties involved, supplemented by
interviews with both appraisal committee members and Institute employees. Necessity is con-
structed differently in the four phases of the appraisal meeting, which, we show, correspond to
four elements of societal weighing rationality. These elements comprise first, allowing explicit cri-
teria to steer the deliberations implicitly. Second, being shaped by the input of patient (represen-
tative)s; these are considered to challenge the process and heighten the quality of the justification
or rationale. Third, bringing in new argumentations from society and weaving them together, and
fourth, formulating recommendations to societal stakeholders to place the decision ‘back’ into
society. These latter two elements of societal weighing rationality, in particular, explicate how
the committee reaches a decision that is well-embedded in society.
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